Rising Tobacco Consumption Fuels Growth In The Non-Small Cell Lung Cancer (NSCLC) Market: The Driving Engine Behind Non-Small Cell Lung Cancer (NSCLC) Market Evolution in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

Non-Small Cell Lung Cancer (NSCLC) Market Size Growth Forecast: What to Expect by 2025?
The market size for non-small cell lung cancer (NSCLC) has seen substantial growth in the past few years. It is projected to expand from $20.1 billion in 2024 to $22.35 billion in 2025, with a compound annual growth rate (CAGR) of 11.1%. The acceleration in growth during the past period is credited to advancements in immunotherapy, genomic profiling, precision medicine, the broadening of clinical trials, and initiatives promoting smoking cessation.

How Will the Non-Small Cell Lung Cancer (NSCLC) Market Size Evolve and Grow by 2029?
Anticipated to witness swift expansion in the coming years, the market size for non-small cell lung cancer (NSCLC) is predicted to reach $33.29 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 10.5%. The progressive surge during the forecast period can be credited to the development of combination therapies, the incorporation of artificial intelligence (AI), the broadening of personalized vaccines, global research collaborations, and a focus on patient-centric care. The forecast period is also set to observe significant trends such as the inclusion of telemedicine in oncology, the progression of liquid biopsy technologies, advancements in diagnostic technologies, the uptake of minimally invasive surgical methods, and immune checkpoint inhibitors.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

What Drivers Are Propelling the Growth of Non-Small Cell Lung Cancer (NSCLC) Market Forward?
The escalation in tobacco use is anticipated to spur the expansion of the non-small cell lung cancer (NSCLC) market. This refers to the utilization of tobacco products which includes smoking, chewing, and ing, thus delivering nicotine and other chemicals into the human system. Tobacco smoke which contains various carcinogens is known to harm the DNA in lung cells, promoting mutations and the unruly enlargement of cancerous cells such as non-small-cell lung cancer (NSCLC). As an illustration, findings from the 2024 National Youth Tobacco Survey by the US Food and Drug Administration (USFDA) in October 2024, showed that 1.1% of all students (roughly 2.25 million) admitted to using tobacco products, 10.1% of high school students (approximately 1.58 million) and 5.4% of middle school students (around 640,000) used tobacco. Additionally, 2.8% of students (about 760,000) reported using any flammable tobacco product, while 3.0% (approximately 840,000) reported using multiple tobacco products. Hence, the upswing in tobacco use acts as a driving factor for the enlargement of the non-small cell lung cancer (NSCLC) market. Non-Small Cell Lung Cancer (NSCLC) Market Driver: Augmenting Air Pollution Levels Tied To Increased Non-Small Cell Lung Cancer (NSCLC) Cases

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp

Which Emerging Trends Are Transforming the Non-Small Cell Lung Cancer (NSCLC) Market in 2025?
Prominent businesses in the non-small cell lung cancer (NSCLC) market are concentrating on the development of a range of treatment alternatives, such as monotherapy treatments, to establish a competitive advantage. Monotherapy treatment refers to the use of a single drug or therapy for a specific illness or ailment, employing a single technique or treatment method rather than a combination of interventions. As an example, in June 2022, the European Commission (EC), a governing authority based in Belgium, granted approval to Novartis AG, a pharmaceutical firm from Switzerland, for Tabrecta (capmatinib), a medication designed to treat adult patients with advanced non-small cell lung cancer with METex14 skipping. This provides a new targeted treatment option for patients in Europe who have received prior treatment and have advanced non-small cell lung cancer (NSCLC) that has mutations leading to MET exon 14 (METex14) skipping. It is currently the most widely used targeted treatment for advanced NSCLC, characterized by changes that cause METex14 skipping.

What Are the Key Segments in the Non-Small Cell Lung Cancer (NSCLC) Market?
The non-small cell lung cancer (NSCLC) market covered in this report is segmented -

1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels

Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp

Who Are the Key Players Shaping the Non-Small Cell Lung Cancer (NSCLC) Market's Competitive Landscape?
Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines

What Geographic Markets Are Powering Growth in the Non-Small Cell Lung Cancer (NSCLC) Market?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.